Concept information
Preferred term
Benserazide
Type
-
mesh:Descriptor
Definition
- An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
Broader concept
Entry terms
- 322-35-0 (Benserazide)
- 762OS3ZEJU
- DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
- DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
- Serazide
- Seryltrihydroxy Benzylhydrazine
- Seryltrihydroxybenzylhydrazine
Allowable Qualifier(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- agonists (Qualifier)
- analogs & derivatives (Qualifier)
- analysis (Qualifier)
- antagonists & inhibitors (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemical synthesis (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- economics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- standards (Qualifier)
- supply & distribution (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- urine (Qualifier)
Pharmacological Action(s)
In other languages
-
French
-
322-35-0 (Benserazide)
-
762OS3ZEJU
-
DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
URI
http://data.loterre.fr/ark:/67375/JVR-FJ6NJ5PV-8
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}